RHJA
HAE icon

Rice Hall James & Associates’s Haemonetics HAE Stock Holding History

Rice Hall James & Associates’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.05M Sell
54,132
-840
-2% -$54.7K 0.17% 130
2025
Q4 		$4.41M Buy
54,972
+2,043
+4% +$137K 0.24% 93
2025
Q3 		$2.58M Sell
52,929
-659
-1% -$40.8K 0.14% 139
2025
Q2 		$4M Sell
53,588
-495
-0.9% -$32.8K 0.22% 97
2025
Q1 		$3.44M Buy
54,083
+7,740
+17% +$526K 0.2% 111
2024
Q4 		$3.62M Sell
46,343
-384
-0.8% -$30.8K 0.2% 121
2024
Q3 		$3.76M Sell
46,727
-604
-1% -$48.8K 0.2% 113
2024
Q2 		$3.92M Sell
47,331
-533
-1% -$46.9K 0.23% 94
2024
Q1 		$4.09M Sell
47,864
-9,157
-16% -$719K 0.23% 91
2023
Q4 		$4.88M Sell
57,021
-812
-1% -$70.2K 0.28% 84
2023
Q3 		$5.18M Buy
57,833
+6,972
+14% +$622K 0.33% 75
2023
Q2 		$4.33M Sell
50,861
-7,853
-13% -$664K 0.25% 98
2023
Q1 		$4.86M Buy
58,714
+6,088
+12% +$493K 0.28% 88
2022
Q4 		$4.14M Sell
52,626
-29,997
-36% -$2.41M 0.24% 97
2022
Q3 		$6.12M Buy
82,623
+5,297
+7% +$380K 0.35% 67
2022
Q2 		$5.04M Buy
77,326
+681
+0.9% +$40.3K 0.24% 83
2022
Q1 		$4.84M Buy
76,645
+18,766
+32% +$1.02M 0.19% 101
2021
Q4 		$3.07M Buy
57,879
+14,647
+34% +$892K 0.11% 173
2021
Q3 		$3.05M Buy
+43,232
New +$2.73M 0.11% 144
2017
Q2 		– Sell
-117,978
Closed -$4.79M – 297
2017
Q1 		$4.79M Sell
117,978
-12,290
-9% -$480K 0.23% 101
2016
Q4 		$5.24M Sell
130,268
-303
-0.2% -$11.4K 0.26% 95
2016
Q3 		$4.73M Buy
130,571
+14,450
+12% +$496K 0.25% 98
2016
Q2 		$3.37M Buy
116,121
+1,645
+1% +$49.7K 0.19% 98
2016
Q1 		$4M Buy
114,476
+3,196
+3% +$103K 0.23% 97
2015
Q4 		$3.59M Buy
111,280
+48,303
+77% +$1.57M 0.21% 108
2015
Q3 		$2.04M Buy
+62,977
New +$2.37M 0.13% 166
2014
Q1 		– Sell
-302,993
Closed -$12.8M – 307
2013
Q4 		$12.8M Buy
302,993
+67,873
+29% +$2.79M 0.92% 44
2013
Q3 		$9.38M Sell
235,120
-22,663
-9% -$951K 0.9% 44
2013
Q2 		$10.7M Buy
+257,783
New +$10.4M 1.05% 35

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rice Hall James & Associates's HAE Position: Q1 2026 in Review

Rice Hall James & Associates reduced its Haemonetics (HAE) stake by 1.5% in Q1 2026, selling an estimated $54.7K and leaving 54,132 shares worth $3.05M. The position accounts for 0.17% of the portfolio, ranked #130.

Rice Hall James & Associates first reported a position in HAE in Q2 2013 and has held it in 29 quarters since. The position peaked at $12.8M in Q4 2013. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Rice Hall James & Associates held 54,132 shares of Haemonetics worth $3.05M as of Q1 2026.
  • Rice Hall James & Associates sold 840 Haemonetics shares in Q1 2026, an estimated $54.7K.
  • Haemonetics made up 0.17% of Rice Hall James & Associates's portfolio in Q1 2026, its #130 holding.
  • Rice Hall James & Associates first reported a position in Haemonetics in Q2 2013 and has held it in 29 quarters since.
  • Rice Hall James & Associates's Haemonetics position peaked at $12.8M in Q4 2013.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.